Clinical Trial Update: Study of Zoladex Given Every 12 Weeks Versus Given Every Month in Advanced Breast Cancer (ABC) Pre-menopausal Women [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing Zoladex (goserelin) given every 12 weeks versus monthly in premenopausal women with advanced breast cancer has completed with results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Zoladex (goserelin)

Snippet

Sponsor: AstraZeneca | Conditions: Advanced Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2011-01-24